Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Ye Yao

Toshihiko Kaneko

Mark Spyvee

Seiichi Kobayashi

Kenzo Muramoto

Kouichi Kikuchi

Motohiro Soejima

Ieharu Hishinuma

Boris M Seletsky

Heather Davis

Wanjun Zheng

Yimin Jiang

André Lescarbeau

Norihito Ohi

Xiang-Yi Li

Bruce Decosta

Fabian Gusovsky

Hiromitsu Yokohama

Marc Pesant

Lynda Tremblay

Yan (Janet) Zhao

Jane Daun

Frank Fang

Charles W Johannes

Xiaojie (jeff) Zhu

The present invention provides compounds having formula (I): 

Deazapurines and uses thereof

As discussed above, there remains a need for the development of novel therapeutic agents useful for treating inflammatory or autoimmune and proliferative diseases. The present invention provides novel compounds of general formula (I), and pharmaceutical compositions thereof, as described generally and in classes and subclasses herein, as well as methods of making and using such compounds.

The present invention provides compounds having formula (I) (and pharmaceutically acceptable derivatives thereof): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R-Rand n are as defined herein.

Luminacin analogs and uses thereof

The present invention provides compounds having formula (I), wherein R, R, Rand n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally 

Growing community of inventors

North Andover, MA, United States of America

Ye Yao